Sellner Johann, Rommer Paulus S
Department of Neurology, Landesklinikum Mistelbach-Gänserndorf, 2130 Mistelbach, Austria.
Department of Neurology, Klinikum rechts der Isar, Technische Universität München, 81675 München, Germany.
Vaccines (Basel). 2021 Jan 28;9(2):99. doi: 10.3390/vaccines9020099.
Several concerns have been raised about the use of immunodepleting agents including alemtuzumab, cladribine and CD20-depleting antibodies in people with multiple sclerosis (pwMS) during the coronavirus disease (COVID) 2019 pandemic. As the end of the pandemic is not yet in sight, vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) may be an elegant strategy to overcome the potential hazards associated with initiating and continuing treatment with immune-depleting agents. In this review, we summarize the immunological effects of immune-depleting therapy and underlying considerations for the hitherto existing recommendations that suggest a restricted use of immune-deleting therapies during the pandemic. Moreover, we critically discuss open questions regarding vaccination in general and against SARS-CoV-2 in pwMS.
在2019年冠状病毒病（COVID-19）大流行期间，人们对在多发性硬化症患者（pwMS）中使用免疫耗竭剂（包括阿仑单抗、克拉屈滨和CD20耗竭抗体）提出了一些担忧。由于大流行尚未结束，接种严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）疫苗可能是一种巧妙的策略，以克服与启动和继续使用免疫耗竭剂治疗相关的潜在危害。在本综述中，我们总结了免疫耗竭疗法的免疫学效应以及迄今现有建议背后的考虑因素，这些建议表明在大流行期间应限制使用免疫耗竭疗法。此外，我们批判性地讨论了关于一般疫苗接种以及pwMS患者接种SARS-CoV-2疫苗的未解决问题。
